AI Engines For more Details: Perplexity Kagi Labs You
Contrast Enhancement: Etifenin is administered orally or intravenously to improve the visualization of the biliary system during imaging studies. It enhances the contrast between the bile ducts and surrounding tissues, aiding in the diagnosis of various biliary tract disorders, including gallstones, bile duct obstructions, and gallbladder diseases.
Cholescintigraphy: Etifenin is commonly used in cholescintigraphy, also known as hepatobiliary scintigraphy or HIDA scan (hepatobiliary iminodiacetic acid scan). During this procedure, a radioactive tracer labeled with etifenin is injected intravenously, and its uptake and excretion by the liver and biliary system are monitored using a gamma camera. This imaging technique helps evaluate the function and patency of the biliary tract.
Diagnostic Imaging: Etifenin-enhanced imaging studies provide valuable information about the anatomy, function, and pathology of the liver, gallbladder, and bile ducts. It is particularly useful in diagnosing conditions such as acute cholecystitis, chronic cholecystitis, biliary dyskinesia, and biliary leaks.
Safety Profile: Etifenin is generally well-tolerated when used as a contrast agent for diagnostic imaging. Adverse reactions are rare but may include allergic reactions, such as rash, itching, or hives, as well as more severe reactions like anaphylaxis. Patients with a history of allergies or sensitivity to contrast agents should be closely monitored.
Contraindications: Etifenin should not be administered to patients with known hypersensitivity to the drug or any of its components. Additionally, caution is advised in patients with severe liver impairment or acute liver disease, as impaired hepatic function may affect the metabolism and excretion of etifenin.
Radiation Exposure: As etifenin is often used in conjunction with radioactive tracers for nuclear medicine imaging, patients may be exposed to ionizing radiation during cholescintigraphy. However, the benefits of the diagnostic information obtained from the procedure generally outweigh the risks associated with radiation exposure.
Medical Supervision: Etifenin-enhanced imaging studies should be performed under the supervision of qualified healthcare professionals, including radiologists and nuclear medicine specialists. Proper patient preparation, monitoring, and post-procedural care are essential to ensure the safety and efficacy of the imaging procedure.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Escherichia | genus | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
| 0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
| 0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
| 0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
| 0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
| 0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
| 0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
| 0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
| 0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
| 0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
| 0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
| 0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
| 0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O111 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O121 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O155 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O177 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O26 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O3 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O5 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O86 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O91 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O103 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O78 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O43 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O119 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O157 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O145 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
| 0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
| 0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
| 0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
| 0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
| 0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
| 0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
| 0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
| 0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
| 0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
| 0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
| 0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
| 0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli H20 | serotype | Decreases |
| 0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
| 0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
| 0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
| 0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
| 0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
| 0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
| 0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
| 0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
| 0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Escherichia coli | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.6 | 0.7 | -0.17 |
| ADHD | 3.7 | 0.9 | 3.11 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 1.1 | |
| Allergic Rhinitis (Hay Fever) | 1.7 | 1.5 | 0.13 |
| Allergies | 4 | 3.8 | 0.05 |
| Allergy to milk products | 1.2 | 1.2 | 0 |
| Alopecia (Hair Loss) | 0.9 | 0.9 | |
| Alzheimer's disease | 4.6 | 4.4 | 0.05 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3 | 0.9 | 2.33 |
| Ankylosing spondylitis | 2.7 | 1.2 | 1.25 |
| Anorexia Nervosa | 0.6 | 1.7 | -1.83 |
| Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
| Asthma | 3.5 | 2 | 0.75 |
| Atherosclerosis | 1.5 | 1.5 | 0 |
| Atrial fibrillation | 2.3 | 1.2 | 0.92 |
| Autism | 5.3 | 5.9 | -0.11 |
| Autoimmune Disease | 0.9 | 0.8 | 0.13 |
| Barrett esophagus cancer | 0.6 | 0.6 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.5 | 0.5 | |
| Bipolar Disorder | 1.5 | 1.7 | -0.13 |
| Brain Trauma | 0.6 | 1.4 | -1.33 |
| Breast Cancer | 0.8 | 0.3 | 1.67 |
| Cancer (General) | 0.9 | 1.5 | -0.67 |
| Carcinoma | 3.7 | 2 | 0.85 |
| Celiac Disease | 1.1 | 2.9 | -1.64 |
| Cerebral Palsy | 0.9 | 1.1 | -0.22 |
| Chronic Fatigue Syndrome | 3 | 2.6 | 0.15 |
| Chronic Kidney Disease | 3.1 | 1.8 | 0.72 |
| Chronic Lyme | 0.3 | 0.8 | -1.67 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 1.7 | -0.89 |
| Chronic Urticaria (Hives) | 0.9 | 0 | 0 |
| Coagulation / Micro clot triggering bacteria | 0.6 | 0.8 | -0.33 |
| Cognitive Function | 2.3 | 1.1 | 1.09 |
| Colorectal Cancer | 5.4 | 2 | 1.7 |
| Constipation | 1.5 | 1.4 | 0.07 |
| Coronary artery disease | 1.2 | 1.7 | -0.42 |
| COVID-19 | 5.1 | 5.8 | -0.14 |
| Crohn's Disease | 4.6 | 4.1 | 0.12 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.6 | 1.6 | -1.67 |
| d-lactic acidosis (one form of brain fog) | 0 | 0 | |
| deep vein thrombosis | 2 | 1.1 | 0.82 |
| Denture Wearers Oral Shifts | 0.6 | 0.6 | |
| Depression | 6.2 | 6.6 | -0.06 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 1.2 | 1.4 | -0.17 |
| Endometriosis | 2.1 | 2 | 0.05 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 1.8 | 0.6 | 2 |
| erectile dysfunction | 1.2 | 0.3 | 3 |
| Fibromyalgia | 1.7 | 1.2 | 0.42 |
| Functional constipation / chronic idiopathic constipation | 3.7 | 2.1 | 0.76 |
| gallstone disease (gsd) | 1.8 | 1.1 | 0.64 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.8 | 0.3 | 1.67 |
| Generalized anxiety disorder | 1.8 | 2 | -0.11 |
| Gout | 1.5 | 1.2 | 0.25 |
| Graves' disease | 1.5 | 2.9 | -0.93 |
| Gulf War Syndrome | 0.3 | 0.4 | -0.33 |
| Halitosis | 1.1 | 1.1 | |
| Hashimoto's thyroiditis | 3 | 1.3 | 1.31 |
| Heart Failure | 2.7 | 1.2 | 1.25 |
| hemorrhagic stroke | 0.9 | 0.9 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 0.6 | 0.6 | 0 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0 | 0 |
| hyperglycemia | 1.6 | 0.6 | 1.67 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 3.1 | 4.4 | -0.42 |
| Hypothyroidism | 0 | 0.9 | 0 |
| Hypoxia | 1.8 | 0.3 | 5 |
| IgA nephropathy (IgAN) | 1.2 | 2.6 | -1.17 |
| Inflammatory Bowel Disease | 4.2 | 5.4 | -0.29 |
| Insomnia | 1.7 | 1.8 | -0.06 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 0.9 | 0.9 | 0 |
| Irritable Bowel Syndrome | 4.6 | 3.2 | 0.44 |
| ischemic stroke | 1.8 | 1.4 | 0.29 |
| Liver Cirrhosis | 5.1 | 3.6 | 0.42 |
| Long COVID | 3.2 | 6.3 | -0.97 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.6 | 0.9 | -0.5 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.8 | 0.9 | -0.13 |
| ME/CFS with IBS | 0.1 | 0.7 | -6 |
| ME/CFS without IBS | 0.3 | 1.2 | -3 |
| Menopause | 1.7 | 0.6 | 1.83 |
| Metabolic Syndrome | 4.7 | 5.4 | -0.15 |
| Mood Disorders | 6 | 4.8 | 0.25 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 3.9 | 2.4 | 0.63 |
| Multiple system atrophy (MSA) | 0.7 | 0.6 | 0.17 |
| myasthenia gravis | 0.6 | 0.5 | 0.2 |
| neuropathic pain | 0.3 | 2.6 | -7.67 |
| Neuropathy (all types) | 0.3 | 2.5 | -7.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4 | 3.5 | 0.14 |
| NonCeliac Gluten Sensitivity | 1.2 | 0.6 | 1 |
| Obesity | 7.3 | 5.6 | 0.3 |
| obsessive-compulsive disorder | 2.9 | 2.2 | 0.32 |
| Osteoarthritis | 0.9 | 0.9 | 0 |
| Osteoporosis | 2.9 | 1.2 | 1.42 |
| pancreatic cancer | 1.7 | 0.3 | 4.67 |
| Parkinson's Disease | 6.1 | 4.5 | 0.36 |
| Polycystic ovary syndrome | 3.1 | 2.3 | 0.35 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.6 | 0.6 | |
| primary biliary cholangitis | 0.9 | 0.6 | 0.5 |
| Primary sclerosing cholangitis | 1.2 | 0.6 | 1 |
| Psoriasis | 1.6 | 1.2 | 0.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.8 | 3.1 | 0.87 |
| Rosacea | 1 | 0.8 | 0.25 |
| Schizophrenia | 5 | 2.3 | 1.17 |
| scoliosis | 0.3 | 0.9 | -2 |
| Sjögren syndrome | 1.5 | 1.7 | -0.13 |
| Sleep Apnea | 2 | 1.7 | 0.18 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 0.6 | 1 |
| Stress / posttraumatic stress disorder | 2 | 1.8 | 0.11 |
| Systemic Lupus Erythematosus | 2.3 | 1.7 | 0.35 |
| Tic Disorder | 0.6 | 1.2 | -1 |
| Tourette syndrome | 0.6 | 0.3 | 1 |
| Type 1 Diabetes | 2.9 | 3.2 | -0.1 |
| Type 2 Diabetes | 5.1 | 4.5 | 0.13 |
| Ulcerative colitis | 2.9 | 3.6 | -0.24 |
| Unhealthy Ageing | 3.1 | 1.4 | 1.21 |
| Vitiligo | 1.2 | 0.4 | 2 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]